Close menu




June 2nd, 2020 | 05:58 CEST

Memphasys, Moderna, Paion - Investments in solutions with potential

  • Healthcare
Photo credits: pixabay.com

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.

time to read: 1 minutes | Author: Mario Hose
ISIN: AU000000MEM5 , US60770K1079 , DE000A0B65S3

Table of contents:


    Biological separation

    Memphasys from Australia has developed a solution for parents with a desire to have children, which allows high-quality sperm to be biologically separated from the man's seminal fluid. The product from Memphasys is called FELIX and increases the chances of success of artificial insemination. The company thus serves a growth market, as more and more couples are deciding to start their professional career first when planning their lives. With increasing age, however, the chance of success of a natural pregnancy decreases and the advice of experts is sought.

    In the second half of 2020, FELIX is to be launched in various countries around the globe. The biological separation process not only works with humans, but can also be used with mammals in the future - also a huge market, according to Alison Coutts Memphasys' market capitalization is currently AUD 52 million at AUD 0.07 per share. The shares are also traded in Germany.

    Covid-19 vaccine hope

    The US biotech company Moderna is in the public eye as it is working on a vaccine against Covid-19, and since the outbreak of the Corona Pandemic, the value of its shares has already risen by around 200%, and at USD 62 per share, its market value is over USD 23 billion. In a recent announcement, the company provided information on the development status. The mid-stage clinical trials have started with 600 patients. Moderna has been researching a vaccine candidate since March 2020 and people are hopeful that a vaccine will provide a way out of the Corona Crisis.

    Approval for anaesthetics

    The Paion shares are also hot at the moment. The company may receive approval for the anesthetic Remimazolam from the US Food and Drug Administration (FDA) in the coming months. "In 2020, Paion's focus will be on evaluating the European Phase III study in general anaesthesia, the regulatory approval process in the US, Europe and other regions, the development of the supply chain and commercial manufacturing of Remimazolam, as well as the market preparation and launch of Remimazolam in different territories," the company announced. Paion's most recent liquidity was approximately EUR 18 million and its share price of EUR 2.29 represents a market value of EUR 143 million.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 7th, 2023 | 07:00 CET

    New developments in the healthcare market: Cardiol Therapeutics, Amazon and Bayer shares in focus

    • Biotechnology
    • Pharma
    • Healthcare

    Cardiol Therapeutics, a clinical-stage life sciences company focusing on therapies for heart inflammation, has secured a renowned clinic to advance its Phase II MAvERIC-Pilot study. This study, focused on combating recurrent pericarditis, promises to provide sound approaches to improve the quality of life of affected patients. Amazon has been dabbling in the healthcare sector since 2015 and is gradually conquering the telemedicine market. The path to telemedicine for Prime members, through the acquisition of companies such as "One Medical" and "PillPack", poses challenges. In contrast, Bayer is once again caught in the crossfire of legal disputes. The recent glyphosate trial loss before a jury in Philadelphia calls for a strategic realignment. At the same time, Bayer is attempting to provide new impetus in the area of women's health through a partnership in the field of hormonal contraception. Find out which development holds promise here.

    Read

    Commented by Juliane Zielonka on November 23rd, 2023 | 07:20 CET

    Saturn Oil + Gas, Rheinmetall, Bayer - Energy, Defense, Healthcare: Where short-term returns await

    • Mining
    • Oil
    • defense
    • Healthcare

    In Germany, the federal government put its spending on hold, a day after the Federal Constitutional Court ruled that the reallocation of EUR 60 billion of unused debt from the pandemic era to the Energy and Climate Fund was unlawful. Europe's largest economy is shrinking due to rising energy prices and trade tensions. At the same time, North America, with stable oil companies such as Saturn Oil & Gas, presents an attractive investment opportunity for investors. Rheinmetall is experiencing a target price high of EUR 370 and flirting with long-term prospects in the US. At the same time, Bayer grapples with legal challenges and the failure of the blood thinner 'asundexian'. We look at where an investment may be worthwhile now.

    Read

    Commented by Juliane Zielonka on November 10th, 2023 | 09:15 CET

    Healthcare and Logistics in Focus with Amazon, First Hydrogen, Bayer - Where growth is created

    • Hydrogen
    • greenhydrogen
    • Logistics
    • Healthcare
    • Technology

    Telemedicine is a blessing for anyone lying in bed with a fever and in need of a doctor or medication. Now, 167 million Americans can benefit from it. Amazon rolled out the telemedicine service to all Prime members in the States this week. To ensure that deliveries arrive on time and with as few emissions as possible, First Hydrogen has developed a van that has already successfully passed its test phase in the UK. A range of 630 km can be covered on one hydrogen charge. But that is not all; the Company is planning much more in the field of hydrogen. After sobering figures, Bayer AG is focusing on drastic measures instead of innovations, but these will benefit those who truly do their job. We take a glance at the details.

    Read